Spring 2007: IDev Technologies: RiverVest leads investment in promising treatment for peripheral artery disease
RiverVest Venture Partners recently led a $19 million Series B financing round for IDev Technologies, Inc., an emerging leader in the treatment of peripheral artery disease (PAD) through the development and marketing of the SUPERA stent system. Joining RiverVest in the Series B round was Bay City Capital, a San Francisco based venture capital firm.
